Immune-inflammatory skin diseases (e.g., psoriasis, atopic dermatitis) involve dysregulation of CD4+ T-cell subsets (Th1/Th2/Th17/Treg) and cytokine networks (IL-17/IL-23/IL-4). Biologics targeting ...

Applying a daily emollient on infants younger than aged 9 weeks reduced the risk for atopic dermatitis by 16% at 24 months ...

Children/adolescents with atopic dermatitis and a sleep disorder faced a greater risk for ADHD, anxiety, depression and ...

In an update to the guidelines for managing atopic dermatitis in adults, four new treatment recommendations are presented.

Immunoinflammatory skin diseases are characterized by an imbalance in immune homeostasis, and their chronic inflammatory processes involve a complex regulatory network of CD4+ T cell differentiation.

A total of 4 new recommendations are included as part of the American Academy of Dermatology’s atopic dermatitis guideline updates.

A poster at the Society for Pediatric Dermatology Annual Meeting presented an integrated safety analysis showing rare or no serious adverse events linked to topical Janus kinase inhibitor use in ...

The efficacy of ruxolitinib cream in pediatric patients shows that nonsteroidal management of atopic dermatitis is feasible, ...

The use of dupilumab for the treatment of atopic dermatitis was associated with an increased risk of psoriasis compared with other systemic agents. The association between dupilumab and psoriasis ...

These studies should provide important mechanistic insights. The long-term immunological effects of repeated intranasal mAb administration were not assessed as the study focused on acute allergic ...

Connect Biopharma is a global, clinical-stage biopharmaceutical company dedicated to developing innovative therapies and transforming care for the treatment of inflammatory diseases. The Company’s ...